Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.71 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL996532 | 1.00 | HRH3 (0.71) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL28282914 | 0.98 | HRH3 (0.68) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL738784 | 0.98 | HRH3 (0.67) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL7356340 | 0.93 | HRH3 (0.60) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL27745775 | 0.90 | HRH3 (0.57) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL4277270 | 0.84 | HRH3 (1.00) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| Hydrochloric Acid SCHEMBL7468055 | 0.81 | HRH3 (0.95) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL18227661 | 0.81 | CHKA (0.70) | HRH3ALDH1A1KDM4ENCF1POLB | |
| SCHEMBL11201497 | 0.81 | HRH3 (0.94) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| Water SCHEMBL28324406 | 0.80 | SIGMAR1 (0.74) | HRH3HRH4ALDH1A1KDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237407-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| CN-107250116-A | 3,5 diamino-pyrazole kinase inhibitors | 埃克希金医药品有限公司 | 2017-10-13 | — | — | CN | claimed |
| US-9730914-B2 | 3,5-diaminopyrazole kinase inhibitors | Axikin Pharmaceuticals (US) | 2017-08-15 | — | — | US | claimed |
| CN-106636043-A | Preparation method of protease | 广州立白企业集团有限公司 | 2017-05-10 | — | — | CN | claimed |
| US-20170087131-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2017-03-30 | — | — | US | claimed |
| US-9546163-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | claimed |
| WO-2016106309-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | WO | claimed |
| US-20160176857-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | claimed |
| EP-2456435-B1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | UNIV LELAND STANFORD JUNIOR (US) | 2015-06-24 | — | — | EP | claimed |
| EP-2403853-B1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2013-08-14 | — | — | EP | claimed |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | claimed |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS, INC. | 2003-09-25 | — | — | US | claimed |
| EP-1319001-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | claimed |
| WO-2002024694-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2002-03-28 | — | — | WO | claimed |
| US-5616711-A | REACTING BUTENE DERIVATIVE TO AN AMIDE DERIVATIVE; USEFUL AS INTERMEDIATES FOR PRODUCING ANTIULCER DRUGS | FUJIREBIO INC. (JP) | 1997-04-01 | — | — | US | claimed |
| EP-0582304-A2 | Methods of producing amino butene derivatives | FUJIREBIO Inc. (JP) | 1994-02-09 | — | — | EP | claimed |
| EP-0150073-B1 | 3,4-DISUBSTITUTED-1,2,5-OXADIAZOLES HAVING HISTAMINE H2-RECEPTOR ANTAGONIST ACTIVITY | Bristol-Myers Squibb Company (US) | 1990-09-26 | — | — | EP | claimed |
| US-4772704-A | ANTIULCER AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-09-20 | — | — | US | claimed |
| EP-0150073-A1 | 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2-receptor antagonist activity | Bristol-Myers Squibb Company (US) | 1985-07-31 | — | — | EP | claimed |
| US-4507485-A | 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity | BRISTOL-MYERS COMPANY (US) | 1985-03-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | NR1H2, NR1H3, NCOA1 | HRH3 1248/4885HRH4 848/4885ALDH1A1 2744/4885 |
| US-20170087131-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, PRKAG3 | HRH3 2223/4885HRH4 1541/4885ALDH1A1 2717/4885 |
| US-20160176857-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, PRKAG3 | HRH3 2223/4885HRH4 1541/4885ALDH1A1 2717/4885 |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | PDXK, GCK, IAPP | HRH3 3252/4885HRH4 1608/4885ALDH1A1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.